盆腔静脉疾病腔内治疗的长期临床有效性
本研究回顾性分析521例盆腔静脉疾病女性患者,比较单纯卵巢静脉栓塞、栓塞联合髂静脉支架及单纯支架的长期镇痛效果。结果显示所有治疗组疼痛均持续改善至36个月,联合治疗组1个月即达最大缓解,而单一治疗组需3个月。
要点
- 盆腔静脉疾病患者常同时存在盆腔和下肢静脉症状。
- 联合卵巢静脉栓塞和髂静脉支架1个月即达最大疼痛缓解并维持36个月。
- 单一治疗需3个月达最大缓解,若分期治疗建议3个月时评估支架。
核心结论
- 无论症状类型或治疗方式,患者疼痛改善并维持至36个月。
- 联合卵巢静脉栓塞和髂静脉支架在1个月即达最大疼痛缓解并维持36个月。
- 单一栓塞或支架需3个月达最大缓解,分期治疗时建议3个月考虑支架。
研究设计与样本
- 纳入521例继发于髂静脉狭窄和/或卵巢静脉反流的盆腔静脉疾病女性。
- 按症状分为盆腔痛组33例、腿痛组208例、混合组280例,比较不同治疗方式。
主要发现
- 盆腔痛和混合痛患者较腿痛患者年轻(P ≤ .001)。
- 盆腔和腿痛患者子宫内膜异位症和卵巢囊肿患病率更高(P ≤ .001)。
- 所有治疗组疼痛评分均显著改善(P ≤ .001)。
- 联合治疗组1个月疼痛显著减轻,维持至36个月无进一步下降(P ≤ .001)。
- 单一治疗组疼痛减轻至3个月,维持至36个月无进一步下降(P ≤ .001)。
关键数值与推荐
- 骨盆痛组术前VAS:支架+栓塞3.07 ± 3.71,单纯栓塞5.27 ± 3.2。
- 腿痛组术前VAS:单纯支架6.18 ± 3.07。
- 混合组术前VAS:单纯支架7.47 ± 2.28,栓塞+支架6.67 ± 2.56。
临床怎么用
- 对卵巢静脉反流合并髂静脉狭窄的患者,联合治疗可更快缓解疼痛。
- 若采用分期方案(先栓塞后支架),建议在3个月时考虑支架,因6个月无进一步改善。
局限性
- 回顾性研究设计。
- 单中心数据。
- 排除接受静脉成形术或静脉成形术联合栓塞的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endovenous therapies are the current standard of care for managing pelvic venous disorders (PeVD) secondary to pelvic venous insufficiency. We previously reported superior short-term results after iliac vein stenting (ST) compared with ovarian vein embolization (OVE). The purpose of this investigation is to determine the long-term durability and clinical effectiveness of endovenous therapies for PeVDs and to identify the time point at which maximal pain reduction is observed. METHODS: A retrospective review of prospectively collected data at the Center for Vascular Medicine from October 2016 to October 2022 was performed. Women with a PeVD secondary to an iliac vein stenosis and/or ovarian vein reflux were included. Assessments and interventions consisted of an evaluation for other causes of PeVD by a gynecologist, Clinical-Etiology-Anatomy-Pathophysiology, pre-, 1, 3, 6, 12, 24, and 36 months postoperative visual analog pain scores, transabdominal duplex ultrasound stent surveillance, stent type, diameter, and length. Patients were separated into three treatment groups: pelvic pain alone, leg pain alone or pelvic, and leg pain and analyzed according to treatment type. Patients treated with venoplasty or venoplasty and OVE were excluded. Differences between groups were analyzed using analysis of variance. RESULTS: A total of 521 women with a PeVD were evaluated and treated with either OVE alone, OVE and ST or ST alone: pelvic pain (n = 33), leg pain (n = 208), and pelvic plus leg (Mixed; n = 280). The average age of the cohort was 52 ± 13.4. Patients with pelvic and mixed pain were younger compared with patients with leg (P ≤ .001). No racial differences by symptom presentation were observed. Patients with pelvic and leg symptoms had a higher prevalence of endometriosis and ovarian cysts (P ≤ .001). The average preintervention ST, OVE and OVE plus ST visual analog scale scores by presentation were the following: pelvic (ST plus OVE, 3.07 ± 3.71; OVE, 5.27 ± 3.2), leg (ST, 6.18 ± 3.07), Mixed (ST, 7.47 ± 2.28; OVE plus ST, 6.67 ± 2.56). Significant improvements in pain scores were observed in all treatment groups. Regardless of the symptom presentation, patients who received OVE plus ST demonstrated significant pain reduction at 1 month with no further decrement in pain that was sustained up to 36 months (P ≤ .001). Patients with ST and OVE alone demonstrated pain reduction up to 3 months with no further pain decrement that was sustained up to 36 months (P ≤ .001). CONCLUSIONS: Women with PeVD often present with concomitant pelvic and lower-extremity venous symptoms. Regardless of the symptomatology or treatment modality, patients report improved and sustained symptom relief up to 36 months. Patients receiving OVE plus ST demonstrated maximal pain reduction at 1 month with sustained relief up to 36 months, whereas patients with OVE or ST alone required 3 months for maximal and sustained pain reduction. These data suggest that combined therapies provide faster pain relief in patients with ovarian vein reflux and iliac vein stenoses. If a staged approach with OVE followed by ST is used, ST should be considered at 3 months as no further improvement at 6 months was observed.
引用
- Ma N, Lakhanpal G, Kennedy R, et al. Long-term clinical effectiveness of endovenous interventions for pelvic venous disorders. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42556527. doi:10.1016/j.jvsv.2026.102597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。